

- (x) CDR3 comprising or consisting of SEQ ID NO: 236;  
CDR2 comprising or consisting of SEQ ID NO: 235;  
CDR1 comprising or consisting of SEQ ID NO: 226;
- (xi) CDR3 comprising or consisting of SEQ ID NO: 238;  
CDR2 comprising or consisting of SEQ ID NO: 237;  
CDR1 comprising or consisting of SEQ ID NO: 232;
- (xii) CDR3 comprising or consisting of SEQ ID NO: 241;  
CDR2 comprising or consisting of SEQ ID NO: 240;  
CDR1 comprising or consisting of SEQ ID NO: 239;
- (xiii) CDR3 comprising or consisting of SEQ ID NO:  
236; CDR2 comprising or consisting of SEQ ID NO:  
235; CDR1 comprising or consisting of SEQ ID NO:  
226;
- (xiv) CDR3 comprising or consisting of SEQ ID NO: 244;  
CDR2 comprising or consisting of SEQ ID NO: 243;  
CDR1 comprising or consisting of SEQ ID NO: 242;

- (xv) CDR3 comprising or consisting of SEQ ID NO: 234;  
CDR2 comprising or consisting of SEQ ID NO: 233;  
CDR1 comprising or consisting of SEQ ID NO: 232;
- (xvi) CDR3 comprising or consisting of SEQ ID NO: 247;  
CDR2 comprising or consisting of SEQ ID NO: 246;  
CDR1 comprising or consisting of SEQ ID NO: 245;  
and
- (xvii) CDR3 comprising or consisting of SEQ ID NO:  
249; CDR2 comprising or consisting of SEQ ID NO:  
248; CDR1 comprising or consisting of SEQ ID NO:  
217.

**24.** The method of claim **12**, wherein the antibody comprises a VHH domain and wherein the VHH domain comprises or consists of the amino acid sequence represented by any one of SEQ ID NOs: 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265 or 266, or an amino acid sequence at least 90%, 95%, 97%, 98% or 99% identical thereto.

\* \* \* \* \*